Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
Pharma News
FDA Announces Plan to Phase Out Animal Testing. Will That Work?
Human organs-on-chips and organoids offer new alternatives to animals for drug development, but there is still a long way to go.
Sino Biopharma spends $951m to acquire China-based LaNova Medicines
Sino Biopharma spends $951m to acquire China-based LaNova Medicines
FDA to review MSD’s doravirine/islatravir NDA for HIV-1
FDA to review MSD’s doravirine/islatravir NDA for HIV-1
FDA Receives Resubmitted BLA
FDA Receives Resubmitted BLA for Tabelecleucel in EBV+ Post-Transplant Lymphoproliferative Disease
Aviva Biopharm Inc.
Aviva Biopharm Inc. Unveils Groundbreaking Pre-Clinical Data on d3-T, a First-in-Class Testosterone Therapy for Women at ENDO 2025
FDA Grants Orphan Drug Designation to Quemliclustat in Pancreatic Cancer
Quemliclustat plus gemcitabine and nab-paclitaxel chemotherapy outperformed median OS benchmarks in patients with metastatic PDAC.
FDA-approved drug can reduce post-surgery pain without heavy opioid use
Researchers at the Medical University of South Carolina have made a breakthrough in pain management.
CTO East Coast 2025
CTO East Coast 2025: Global oncology cell therapy market to hit $25bn by 2031
FDA accepts new supplemental biologics license application for review for Winrevair
The FDA has accepted for priority review a new supplemental biologics license application for Winrevair to treat adults with advanced pulmonary arterial hypertension, according to a press release from...
China's Everest Medicines
China's Everest Medicines Unveils Positive Preclinical Validations of In Vivo CAR-T Program
Harmony Biosciences Preclinical Data for Narcolepsy Drug BP1.15205 Shows Promise
Harmony Biosciences Holdings Inc. (NASDAQ:HRMY) is one of the most undervalued small-cap stocks to buy according to analysts.
Klotho Neurosciences’ ALS therapy awarded FDA Orphan Drug Designation
Klotho Neurosciences announced that its novel therapy KLTO-202, also known as s-KL-AAV.myo, for the treatment of Amyotrophic Lateral Sclerosis (ALS) has received Orphan
35
36
37
38
39
40
41
42
43
